OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
October 19, 2015.
The treatment market for glaucoma will rise in value from $2.4 billion in 2013 to approximately $3 billion by 2023 across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, UK, and Japan, according to a new report. The growth represents a moderate overall CAGR of 2.4%.
EpiCast Report: Glaucoma: Epidemiology Forecast to 2023 states that growth will be driven by the arrival of innovative first-in-class drugs, such as Rhopressa/Roclatan, Vesneo, and trabodenoson, and the introduction of additional fixed-dose combination (FDC) products, such as Tapcom/Taptiqom and Simbrinza, during the forecast period.
Changing population demographics in the 7MM is contributing to the increase in the number of cases of glaucoma; however, the report argues, further epidemiological research is needed as there is a paucity of national and international data evaluating the prevalence and trends of glaucoma worldwide.